Aquestive Therapeutics to Participate in Two Investor Conferences in September
August 31, 2022 16:02 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...
Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film
August 31, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
Libervant provided tentative approval from the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activityLibervant U.S. Market Access currently subject to the...
Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space
August 10, 2022 16:50 ET
|
Aquestive Therapeutics, Inc.
Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of...
Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 02, 2022 16:02 ET
|
Aquestive Therapeutics, Inc.
Completed EPIPHAST trial successfully demonstrating rapid and significant epinephrine exposure under a variety of real-world conditions after administration of AQST-109 (epinephrine sublingual...
Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference
July 26, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...
Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8:00 a.m. ET
July 20, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film
July 11, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
Study results for the sublingual administration of AQST-109 epinephrine oral film after consuming a peanut butter sandwich demonstrates consistent Tmax of 12 minutesStudy results for swallowing...
Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
June 15, 2022 16:22 ET
|
Aquestive Therapeutics, Inc.
AQST-109 is the first and only orally delivered epinephrine product candidate in clinical developmentFastest median time to maximum concentration (Tmax) in studies to date at 12 minutes Study...
Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering
June 08, 2022 16:01 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
Aquestive Therapeutics to Participate in JMP Securities Life Sciences Conference
June 07, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...